Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. (2021)

First Author: Humby F
Attributed to:  Centre for Integrated research into Musculoskeletal Ageing (CIMA) Renewal funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(20)32341-2

PubMed Identifier: 33485455

Publication URI: http://europepmc.org/abstract/MED/33485455

Type: Journal Article/Review

Volume: 397

Parent Publication: Lancet (London, England)

Issue: 10271

ISSN: 0140-6736